Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATR inhibitor AZD6738 in combination with olaparib in relapsed gynecological cancers with or without ARID1A loss
2018-003779-36Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceralasertib and olaparib in clear cell ovarian cancer, clear cell endometrial carcinoma (CCEC), Endometrioid Cystadenocarcinoma and 6 more (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Confirmed overall objective response rate. Status: unknown.
02
Drugs
ceralasertibolaparib
03
Conditions
clear cell ovarian cancerclear cell endometrial carcinoma (CCEC)Endometrioid Cystadenocarcinomaendometrioid adenocarcinomaovarian carcinosarcoma (OCS)
Beyond the preview
Go deeper on 2018-003779-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003779-36.